Pulmonx Corp Stock Performance
| LUNG Stock | USD 7.86 0.09 1.16% |
On a scale of 0 to 100, Pulmonx Corp holds a performance score of 7. The company holds a Beta of -0.22, which implies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Pulmonx Corp are expected to decrease at a much lower rate. During the bear market, Pulmonx Corp is likely to outperform the market. Please check Pulmonx Corp's semi variance, and the relationship between the treynor ratio and daily balance of power , to make a quick decision on whether Pulmonx Corp's historical price patterns will revert.
Risk-Adjusted Performance
OK
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Pulmonx Corp are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. Despite nearly uncertain basic indicators, Pulmonx Corp reported solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 1.16 | Five Day Return 11.65 | Year To Date Return 20.55 | Ten Year Return (80.01) | All Time Return (80.01) |
1 | Acquisition by Geoffrey Rose of 69100 shares of Pulmonx Corp at 9.3 subject to Rule 16b-3 | 12/23/2024 |
2 | Pulmonx Repeat Insider Selling Not A Positive Indicator | 12/27/2024 |
3 | Disposition of 1184 shares by Geoffrey Rose of Pulmonx Corp at 10.6 subject to Rule 16b-3 | 12/30/2024 |
4 | Disposition of 2221 shares by Glendon French of Pulmonx Corp at 6.5 subject to Rule 16b-3 | 01/17/2025 |
5 | Many Still Looking Away From Pulmonx Corporation | 02/07/2025 |
6 | Epsons Lauren Lung, Director of Commercial Sales, Recognized as a 2025 Channel Chief by CRN | 02/13/2025 |
7 | Pulmonx Corp Q4 2024 Earnings EPS Loss of 0. ... | 02/19/2025 |
8 | Pulmonx Corp Q4 2024 Earnings Call Highlights Strong Revenue Growth Amid Financial ... | 02/20/2025 |
9 | Pulmonx Corporation Just Reported Full-Year Earnings Have Analysts Changed Their Mind On The Stock | 02/21/2025 |
10 | Disposition of 719 shares by David Lehman of Pulmonx Corp at 6.97 subject to Rule 16b-3 | 03/06/2025 |
11 | This Pulmonx Analyst Begins Coverage On A Bullish Note Here Are Top 5 Initiations For Monday | 03/10/2025 |
12 | AccuStem Sciences, Inc. Announces Acquisition of Proprietary MSC Lung Cancer Screening Test | 03/18/2025 |
| Begin Period Cash Flow | 83.8 M | |
| Free Cash Flow | -33 M |
Pulmonx |
Pulmonx Corp Relative Risk vs. Return Landscape
If you would invest 615.00 in Pulmonx Corp on December 20, 2024 and sell it today you would earn a total of 162.00 from holding Pulmonx Corp or generate 26.34% return on investment over 90 days. Pulmonx Corp is currently generating 0.529% in daily expected returns and assumes 5.5846% risk (volatility on return distribution) over the 90 days horizon. In different words, 49% of stocks are less volatile than Pulmonx, and 90% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Pulmonx Corp Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Pulmonx Corp's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Pulmonx Corp, and traders can use it to determine the average amount a Pulmonx Corp's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0947
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | LUNG | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 5.58 actual daily | 49 51% of assets are more volatile |
Expected Return
| 0.53 actual daily | 10 90% of assets have higher returns |
Risk-Adjusted Return
| 0.09 actual daily | 7 93% of assets perform better |
Based on monthly moving average Pulmonx Corp is performing at about 7% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Pulmonx Corp by adding it to a well-diversified portfolio.
Pulmonx Corp Fundamentals Growth
Pulmonx Stock prices reflect investors' perceptions of the future prospects and financial health of Pulmonx Corp, and Pulmonx Corp fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Pulmonx Stock performance.
| Return On Equity | -0.55 | ||||
| Return On Asset | -0.21 | ||||
| Profit Margin | (0.67) % | ||||
| Operating Margin | (0.56) % | ||||
| Current Valuation | 272.17 M | ||||
| Shares Outstanding | 39.8 M | ||||
| Price To Book | 3.70 X | ||||
| Price To Sales | 3.69 X | ||||
| Revenue | 83.79 M | ||||
| Gross Profit | 62 M | ||||
| EBITDA | (57.7 M) | ||||
| Net Income | (56.39 M) | ||||
| Cash And Equivalents | 162.09 M | ||||
| Cash Per Share | 4.35 X | ||||
| Total Debt | 56.47 M | ||||
| Debt To Equity | 0.15 % | ||||
| Current Ratio | 9.43 X | ||||
| Book Value Per Share | 2.16 X | ||||
| Cash Flow From Operations | (31.54 M) | ||||
| Earnings Per Share | (1.44) X | ||||
| Market Capitalization | 309.22 M | ||||
| Total Asset | 162.85 M | ||||
| Retained Earnings | (467.56 M) | ||||
| Working Capital | 111.81 M | ||||
About Pulmonx Corp Performance
By analyzing Pulmonx Corp's fundamental ratios, stakeholders can gain valuable insights into Pulmonx Corp's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Pulmonx Corp has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Pulmonx Corp has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 283.37 | 248.31 | |
| Return On Tangible Assets | (0.35) | (0.37) | |
| Return On Capital Employed | (0.42) | (0.44) | |
| Return On Assets | (0.35) | (0.36) | |
| Return On Equity | (0.66) | (0.62) |
Things to note about Pulmonx Corp performance evaluation
Checking the ongoing alerts about Pulmonx Corp for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Pulmonx Corp help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Pulmonx Corp is way too risky over 90 days horizon | |
| Pulmonx Corp appears to be risky and price may revert if volatility continues | |
| Pulmonx Corp has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 83.79 M. Net Loss for the year was (56.39 M) with profit before overhead, payroll, taxes, and interest of 62 M. | |
| Pulmonx Corp currently holds about 162.09 M in cash with (31.54 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.35. | |
| Pulmonx Corp has a poor financial position based on the latest SEC disclosures | |
| Over 93.0% of the company shares are owned by institutional investors | |
| Latest headline from globenewswire.com: AccuStem Sciences, Inc. Announces Acquisition of Proprietary MSC Lung Cancer Screening Test |
- Analyzing Pulmonx Corp's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Pulmonx Corp's stock is overvalued or undervalued compared to its peers.
- Examining Pulmonx Corp's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Pulmonx Corp's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Pulmonx Corp's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Pulmonx Corp's stock. These opinions can provide insight into Pulmonx Corp's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Pulmonx Stock analysis
When running Pulmonx Corp's price analysis, check to measure Pulmonx Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pulmonx Corp is operating at the current time. Most of Pulmonx Corp's value examination focuses on studying past and present price action to predict the probability of Pulmonx Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pulmonx Corp's price. Additionally, you may evaluate how the addition of Pulmonx Corp to your portfolios can decrease your overall portfolio volatility.
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |